By one measure, healthcare private equity has never been stronger. Deal value hit a record $191 billion in 2025, according to Bain & Company, and exit value rebounded to $156 billion. Dry powder is plentiful, and nearly every large sponsor still wants healthcare in its portfolio.
Look closer at 2026 and the picture changes. Bain counted 184 healthcare buyouts in the first half of the year, up from 173, but total value fell to $51 billion from $61 billion. The number of active funds jumped from 331 to 415. More capital is chasing smaller deals, often at prices that still assume the old playbook works.
It doesn’t. As Bain put it in its midyear update, “revenue expansion and multiple arbitrage are no longer sufficient to propel returns.” For middle-market sponsors, that sentence is the whole story.
For most of the last decade, healthcare returns ran on three engines: cheap leverage, rising exit multiples and steady reimbursement growth. All three have stalled.
Leverage is more expensive and less forgiving. Redemption stress in private credit, the middle market’s main source of financing, has made lenders more selective on smaller and more complex credits. The best assets still get financed on good terms. Everything else waits.
Exit multiples have stopped doing the work. U.S. private equity-backed exits fell to 872 in the first half of 2026, down from 1,210 a year earlier, even as median entry multiples stayed above 13 times EBITDA. Sponsors are holding longer and leaning on continuation vehicles and minority recapitalizations to return capital.
Reimbursement, the third engine, is now running in reverse.
Healthcare always has a payer under pressure. It rarely has all of them at the same time.
Medicaid is the largest change. The 2025 federal reconciliation law will reduce federal health spending by more than $1 trillion over ten years and add about 10 million people to the uninsured by 2034, according to Congressional Budget Office estimates compiled by KFF. Work requirements take effect by December 31, 2026. Limits on provider taxes begin in October 2027, and caps on state-directed payments follow in 2028. For businesses built on Medicaid volume, the question is no longer whether rates hold, but how many members remain.
The individual market is already shrinking. Enhanced ACA premium tax credits expired at the end of 2025. Effectuated marketplace enrollment fell from 22.1 million to 19.2 million, and enrollees’ net premium payments rose 58%. That shows up in provider P&Ls as more self-pay patients and more bad debt.
Medicare is squeezing from both sides. Home health took a 1.3% aggregate cut for 2026, and the proposed 2027 physician fee schedule lowers the conversion factor again. Medicare Advantage rates rose 2.48% for 2027, but plans initially denied about 17% of claims in one large study, and providers spend heavily winning back what they are owed.
The enforcement climate has shifted too. A federal fraud task force created in March 2026 has put Medicaid home care, hospice, behavioral health and autism services under scrutiny. CMS deferred $1.3 billion in California Medicaid funding, the largest deferral in its history, and in May 2026 froze new Medicare enrollment of home health agencies and hospices nationwide.
Ownership is under review as well. More than a dozen states now require notice of, or restrict, private equity healthcare deals, and Oregon has effectively dismantled the friendly-PC structure behind physician roll-ups. Each adds time, cost and risk to deals that once closed on a purchase agreement and a management contract.
None of this makes healthcare uninvestable. It makes it unforgiving. The middle-market sponsors who do well over the next five years are already underwriting differently.
They buy for operations, not the multiple. The value creation plan is specific—recruiting and retaining clinicians, fixing intake and scheduling, tightening the revenue cycle, putting technology to work in documentation—and management owns it from day one.
They favor payer mixes insulated from government rate-setting: commercial and private-pay revenue, or services that make payers and providers more efficient rather than depend on them.
They treat compliance as an asset. In a market where regulators freeze enrollments and defer payments, a clean, well-documented operator is worth more—and harder to find.
They partner with founders rather than flip them. Fragmented, founder-owned businesses still need capital, systems and management depth. A sponsor that brings those, and keeps the founder engaged, has an edge no auction can price.
Healthcare private equity is not broken. The easy version of it is. Capital that expected to earn its return from leverage and exit multiples will be disappointed. Capital that expects to earn it by building better businesses—in segments where demand outruns supply and the payer is not the problem—still has room to run.
The difference between those outcomes will not be decided by who has the most dry powder. It will be decided by who understands the businesses they are buying.
250 Fillmore Street
Denver, CO 80206
50 Milk Street
Boston, MA 02109
970-450-7400
connect@4-cc.com
